AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction

Kidney International

Volumn 80, Issue 2, 2011, Pages 133-135

  Tomino, Yasuhiko ^a   Hagiwara, Shinji ^a   Gohda, Tomohito ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; K 163; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOSIDINE; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; PROTEIN P21; PYRIDOXAMINE; SOMATOMEDIN C; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CHRONIC INFLAMMATION; DIET RESTRICTION; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; NATRIURESIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 79959810354     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.86     Document Type: Note

References (11)

1. Tan AL, Forbes JM, Cooper ME. AGE RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007;27: 130-143. (Pubitemid 46550311)
2. D ' Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6: 352-360.
3. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144: 21-28. (Pubitemid 46780716)
4. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. K idney Int 2001;59: 1498-1509. (Pubitemid 32281241)
5. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41: 625-633. (Pubitemid 36314565)
6. Dengel DR, Goldberg AP, Mayuga RS et al. Insulin resistance, elevated glomerular filtration fraction, and renal injury. H ypertension 1996;28: 127-132. (Pubitemid 26231101)
7. Li SY, Liu Y, Sigmon VK et al. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 2005; 7: 448-454. (Pubitemid 40916588)
8. Hirasawa Y, Matsui Y, Yamane K et al. Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. E xp Anim 2008;57: 423-432.
9. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11: 1656-1666.
10. Harcourt BE, Sourris KC, Coughlan MT et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011; 80: 190-198.
11. Hagiwara S, Gohda T, Tanimoto M et al. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. Metabolism 2009;58: 934-945.